查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179913

2022-2029 年全球透皮给药装置市场

Global Transdermal Drug Delivery Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预计在预测期内（2022-2029 年），透皮给药装置的全球市场规模将显着增长。

药物输送设备是用于输送药物和治疗剂的专用设备。 透皮药物输送装置使用贴在皮肤上的含药粘性皮肤贴剂，将规定量的药物输送到血流中。

市场动态

推动全球透皮贴剂市场发展的主要因素是世界上疾病数量的增加、研发成本的增加以及公众对透皮贴剂益处的认识。 新产品发布的增加有助于透皮给药装置市场的增长。

预计透皮给药系统应用的扩展和新研究数量的增加将推动市场增长。

采用这些透皮给药装置治疗神经和心血管疾病等各种慢性疾病以及新产品的不断推出正在推动透皮给药装置市场。我来了。 此外，世界上越来越多的疾病也在推动市场的增长。 许多医疗保健公司正在加紧研发活动以开发新产品。

之所以使用透皮给药装置，是因为它们优于其他给药途径，例如避免肝臟首过效应、降低给药频率和提高患者依从性。 由于各种疾病的增加，透皮治疗贴剂的市场正在全球范围内扩大。 此外，主要参与者增加对新型补丁和技术先进产品的研究和开发也有望在市场增长中发挥关键作用。

各种新产品的发布、监管批准和研究都为市场的增长做出了贡献。 例如，2022年10月17日，专注于透皮疗法开发的久光製药全资子公司Noven Pharmaceuticals.Inc.荣获第36届美国精神奖在医学护士协会 (APNA) 年会上宣布了两个新药代动力学 (PK) 建模数据集结果的展示。 这些数据旨在研究右苯丙胺透皮系统 (d-ATS) 在治疗注意力缺陷多动障碍 (ADHD) 时的佩戴时间变化以及 d-ATS 从儿科患者到成人的疗效。显示了每个外推。

与透皮给药装置相关的限制预计会阻碍市场增长。

但是，透皮给药贴剂的一个主要限制是它们是亲脂性的，只能输送少量药物。 从皮肤最外层递送高分子量（大于 500 道尔顿）和亲水性药物非常有限。 主动输送系统可以扩大输送范围，但它们需要外部电源并且是笨重的设备。

如果产品被召回，在召回和更换有缺陷产品的过程中，公司和製造商可能会因更换或维修有缺陷的产品而蒙受巨大损失。 如此巨大的损失影响了公司的收入和市场份额，并影响了整个市场。 关键的挑战与其说是技术本身，不如说是製药和医疗器械这两个不同领域的整合。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了负面影响。 COVID-19 的爆发严重影响了医疗保健行业。 由于各种研究和临床试验被推迟，透皮给药装置市场因 COVID 遭受了巨大损失。 迫切需要一种疫苗来防止 COVID 及其变种在世界范围内传播，并引起了人们的关注。 世界各地正在发生各种举措、产品发布、创新、合作和合併，推动了市场的增长。 例如，2020年4月13日，Hisamitsu Pharmaceutical Co., Ltd.的全资子公司Noven Pharmaceuticals, Inc.获得美国食品药品监督管理局（FDA）批准用于治疗精神分裂症患者。宣布其 SECUADO（阿塞那平）透皮系统现在可以在美国通过处方获得。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第4章市场动态

  • 市场影响因素
    • 司机
      • 扩展透皮给药系统的应用领域
      • 新产品发布激增
      • 感染增加
    • 约束因素
      • 与透皮给药装置相关的限制
    • 商机
    • 影响分析

第5章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 水库补丁
  • 矩阵补丁
  • 含有药物的贴片
  • 微针贴片

第8章技术

  • 被动透皮吸收技术
    • 化学增强剂
    • 前药
    • 共晶系统
  • 透皮製剂技术
    • 射频消融治疗
    • 激光热烧灼
    • 电穿孔
    • 离子导入
    • 微针
    • 喷射器
    • 超声波

第 9 章按应用

  • 疼痛管理
  • 激素替代疗法
  • 节育
  • 神经系统疾病
  • 吸烟门诊
  • 心血管疾病
  • 糖尿病
  • 其他

第 10 章最终用户

  • 医院
  • 门诊手术中心
  • 家庭护理

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • 诺华
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Zydus Lifesciences Ltd
  • Boehinger Ingelheim International GmbH
  • AbbVie（Allergan）
  • UCB S.A.
  • Viatris Inc.
  • Noven Pharmaceuticals, Inc.
  • Acrux Limited
  • Purdue Pharma L.P.
  • Endo International plc

第 14 章全球透皮给药装置市场-DataM

简介目录
Product Code: DMMD49

Market Overview

The global transdermal drug delivery devices market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Drug delivery devices are specialized equipment used for the delivery of a drug or therapeutic agent. A transdermal drug delivery device uses a medicated adhesive skin patch that is placed on the skin to deliver a specific dose of medication into the bloodstream.

Market- Dynamics

The major factors driving the global transdermal drug delivery devices market are an increase in the number of diseases globally, rising research and development expenditure and awareness among the population regarding the advantages of transdermal drug delivery devices. An increase in novel product launches contributes to the growth of the transdermal drug delivery devices market.

The expanding areas of application of transdermal drug delivery systems and rising novel research studies are expected to drive the market's growth.

The rising adoption of these transdermal drug delivery devices for the treatment of various chronic diseases, such as neurological or cardiovascular disorders, and many more and the rising number of novel product launches drive the transdermal drug delivery devices market. An increase in diseases globally is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

The transdermal drug delivery devices are used for the advantages it provides over other route of administration drug delivery such as avoiding hepatic first-pass effect reduced dosing frequency and better patient compliance. The market for these patches is increasing worldwide due to the increasing number of different diseases. Moreover, the increase in research and development of novel patches and the availability of technologically advanced products by key players are also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals and research studies contribute to the market's growth. For instance, in October 17, 2022, Noven Pharmaceuticals. Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly owned subsidiary, focusing on the transdermal therapy development, announced about presenting its novel two pharmacokinetic (PK) modeling datasets results at the 36th annual conference of American Psychiatric Nurses Association (APNA). The data shows the investigation of dextroamphetamine transdermal system's (d-ATS) variable wear times for the Attention-Deficit/Hyperactivity Disorder (ADHD) treatment and d-ATS efficacy extrapolation from pediatric patients to adults respectively.

The limitations associated with transdermal drug delivery devices are expected to hamper the market's growth.

However, the major limitation of transdermal drug delivery patches is that they can deliver only lipophilic, small and low-dose drugs. The high molecular weight (more than 500 Dalton) and hydrophilic drug delivery via the skin's outermost layer are highly restrained. The active delivery system can enhance the extent of transmission, but it requires an external power supply, and the devices are bulky as well.

If a product is recalled, the process of retrieving and replacing the defective product may cause a company or a manufacturer to incur huge losses associated with replacing and fixing faulty products. These huge losses will affect the revenue and the company's market share, which will impact the overall market. The key challenges are less about the technology itself and more about integrating two distinct world's pharma and medical device.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transdermal drug delivery devices market has experienced huge losses due to COVID, as various research and clinical trials got postponed. An urgent need for vaccines to prevent the spreading of COVID and its variant across the globe diverted the attention. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in April 13, 2020, Noven Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly owned subsidiary, announced that its SECUADO (asenapine) transdermal system, approved for the treatment of schizophrenia patients by the U.S. Food and Drug Administration (FDA), is now available in the U.S. by prescription.

Segment Analysis

The micro-needle patch segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The micro-needle patch segment is the highest market holder in the global transdermal drug delivery devices market. The global transdermal drug delivery devices market is segmented based on product type: reservoir patch, matrix patch, drug-in adhesive patch and micro-needle patch. The micro-needle patch segment is the largest market shareholder due to its better advantage, efficacy and results, increasing diseases and rising adoption of these transdermal drug delivery devices.

In micro-needle patch with the sharp micro-needles (made up of ceramics and silicon) the skin tissues are pierced. As a result, there is a formation of micro-scale perforation. The perforated surface provides the pharmaceutical active ingredient passage. The micro-needle patch generally is categorized into four types: solid micro-needle, dissolving micro-needle, coated micro-needle, and hollow micro-needle patches. The solid ones are utilized as a pre-treatment for skin to develop micro-scale pores. In coated one micro-needle are directly applied to the skin, from the needle's surface the drug dissolves off and eventually transfers to the body. The dissolving micro-needles are the ones in which drugs are loaded in micro-needles formed of biodegradable polymer.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in December 2, 2022, Zydus Lifesciences Limited announced its approval for Estradiol Transdermal System USP marketing, by the United States Food and Drug Administration (USFDA). Estradiol is utilized for treating menopause symptoms like hot feelings in the neck and chest or strong feelings of heat and vaginal dryness in women. The drug will be produced at the formulation manufacturing site of Zydus Lifesciences at Ahmedabad, India.

Geographical Analysis

North America holds the largest market share in the global transdermal drug delivery devices market.

North America dominates the global transdermal drug delivery devices market, primarily due to its large population, excellent medical infrastructure, and rising number of diseases. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of products such as reservoir patch, matrix patch, drug-in adhesive patch, micro-needle patch, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the transdermal drug delivery devices market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in March 23, 2022, Noven Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc.'s wholly-owned subsidiary, announced that the approval of XELSTRYM (dextroamphetamine) transdermal system, CII from the U.S. Food and Drug Administration (FDA) for Attention-Deficit/Hyperactivity Disorder (ADHD) treatment for adults and pediatric patients. XELSTRYM is the only transdermal amphetamine patch which received FDA-approval.

Competitive Landscape

The transdermal drug delivery devices market is moderately competitive with local and global companies' presence. Novartis AG, Zydus Lifesciences Ltd, Boehinger Ingelheim International GmbH, AbbVie (Allergan), UCB S.A., Viatris Inc., Noven Pharmaceuticals, Inc., Acrux Limited, Purdue Pharma L.P., Endo International plc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in January 5, 20221, Endo International plc announced that Endo Ventures Limited, its subsidiary has entered into agreements with Radius Health, Inc. to commercialize and distribute abaloparatide in Canada. Under the agreement, Endo got the rights to abaloparatide-transdermal patch (abaloparatide-TD), a novel formulation currently undergoing clinical development.

Novartis AG.

Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

EXELON PATCH: Exelon Patch is a rivastigmine transdermal patch indicated for dementia of the Alzheimer's type (AD) and dementia linked with Parkinson's disease (PD).

The global transdermal drug delivery devices market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Expanding areas of application of transdermal drug delivery systems
      • 4.1.1.2. Surge in novel product launches
      • 4.1.1.3. Increasing incidence of infectious diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with transdermal drug delivery devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Reservoir Patch *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Matrix Patch
  • 7.4. Drug-in Adhesive Patch
  • 7.5. Micro-needle Patch

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Passive Transdermal Technology *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Chemical Enhancers
    • 8.2.4. Prodrug
    • 8.2.5. Eutectic Systems
  • 8.3. Active Transdermal Technology
    • 8.3.1. Radiofrequency Ablation
    • 8.3.2. Laser Thermal Ablation
    • 8.3.3. Electroporation
    • 8.3.4. Iontophoresis
    • 8.3.5. Microneedle
    • 8.3.6. Jet Injector
    • 8.3.7. Ultrasound

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Pain Management *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Hormone Replacement Therapy
  • 9.4. Contraception
  • 9.5. Neurological Disorders
  • 9.6. Smoking Cessation
  • 9.7. Cardiovascular Disorders
  • 9.8. Diabetes
  • 9.9. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Homecare Setting

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Novartis *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Zydus Lifesciences Ltd
  • 13.3. Boehinger Ingelheim International GmbH
  • 13.4. AbbVie (Allergan)
  • 13.5. UCB S.A.
  • 13.6. Viatris Inc.
  • 13.7. Noven Pharmaceuticals, Inc.
  • 13.8. Acrux Limited
  • 13.9. Purdue Pharma L.P.
  • 13.10. Endo International plc

LIST NOT EXHAUSTIVE

14. Global Transdermal Drug Delivery Devices Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and End-User
  • 14.3. Contact Us